Skip to content

D&A at other companies

Amgen logo
AmgenAMGN
$1.12B-19.5%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$439K-8.0%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$2.2M-6.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$227K-7.0%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$19.8M+1.5%
Precigen logo
PrecigenPGEN
$1.1M+74.7%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.65B+319%
Enterprise value$1.6B+1,325%
P/S22.8×-379×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s D&A?
Septerna, Inc. (SEPN) reported D&A of $421K in Q1 2026.
How has Septerna, Inc.'s D&A changed year-over-year?
Septerna, Inc.'s D&A increased by 6.0% year-over-year, from $397K to $421K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.